A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)
Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be
treated successfully with the conventional chemotherapy of CHOP. The investigators have been
proceeding this trial to evaluate the efficacy and safety of the combination chemotherapy
regiment DDGP (gemcitabine,pegaspargase, cisplatin, dexamethasone) in the patients with
stage I/II NK/T cell lymphoma.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
up to end of follow-up-phase (approximately 24 months)
No
Mingzhi Zhang, Pro,Dr
Principal Investigator
The First Affiliated Hospital of Zhengzhou University
China: Food and Drug Administration
hnslblzlzx2011
NCT01501136
January 2011
May 2019
Name | Location |
---|